Press Release

Cellectis is awarded the "Best Pharma Partnering" Trophy 2005 by Pharma Industry Association

Romainville, France - October the 18^th, 2005 - During BIORIF 2005, the Fourth Annual Life Sciences & Biotech business meeting in Paris, Cellectis was awarded the "Best Pharma Partnering" Trophy by the French Association of Pharmaceutical Companies (LEEM - Les Entreprises du Medicament).

Cellectis SA was founded in 2000 as a spin-off from Institut Pasteur. Today, it is the world leader in the field of genome engineering and Meganuclease technologies, the ongoing revolution in life sciences. Cellectis develops Meganuclease Recombination Systems to perform DNA surgery in living cells and organisms.

Since inception, Cellectis has entered into more than 35 revenue generating agreements in various fields including tools for the pharmaceutical industry. David J.D. Sourdive, SVP & COO of Cellectis, comments: "We are very proud of this award that underscores the significant contribution of Cellectis' genome engineering products to the pharmaceutical industry. Cellectis' strong market position is built on value-creating partnerships with all bio-industries. We are looking forward to broadening the spectrum of our fruitful collaborations in the future."

About Cellectis SA:

Cellectis (www.cellectis.com) focuses its industrial developments on new Meganucleases for in vivo DNA surgery. The company develops therapeutic applications of its systems, while its commercial offer is centered on industrial applications of new in vivo specific recombination tools.

Cellectis has 35 employees, including 14 Ph. Ds., and has signed more than thirty five commercial contracts on its genome engineering technologies with major players from pharmaceutical, biotechnology and agro-industries.

Copyright © Cellectis 2005. All rights reserved.